Literature DB >> 29993282

Marinobufagenin and left ventricular mass in young adults: The African-PREDICT study.

Michél Strauss1, Wayne Smith1,2, Ruan Kruger1,2, Wen Wei3, Olga V Fedorova3, Aletta E Schutte1,2.   

Abstract

Background The endogenous steroidal inhibitor of sodium-potassium-dependent adenosine triphosphate and natriuretic hormone, marinobufagenin, plays a physiological role in ionic homeostasis. Animal models suggest that elevated marinobufagenin adversely associates with cardiac and renal, structural and functional alterations. It remains uncertain whether marinobufagenin relates to the early stages of target organ damage development, especially in young adults without cardiovascular disease. We therefore explored whether elevated 24-hour urinary marinobufagenin excretion was related to indices of subclinical target organ damage in young healthy adults. Design This cross-sectional study included 711 participants from the African-PREDICT study (black 51%, men 42%, 24.8 ± 3.02 years). Methods We assessed cardiac geometry and function by two-dimensional echocardiography and pulse wave Doppler imaging. 24-Hour urinary marinobufagenin and sodium excretion were measured, and the estimated glomerular filtration rate determined. Results Across marinobufagenin excretion quartiles, left ventricular mass ( P < 0.001), end diastolic volume ( P < 0.001), stroke volume ( P = 0.004) and sodium excretion ( P < 0.001) were higher within the fourth compared with the first quartile. Partial regression analyses indicated that left ventricular mass ( r = 0.08, P = 0.043), end diastolic volume ( r = 0.10, P = 0.010) and stroke volume ( r = 0.09, P = 0.022) were positively related to marinobufagenin excretion. In multivariate-adjusted regression analysis, left ventricular mass associated positively with marinobufagenin excretion only in the highest marinobufagenin excretion quartile (adjusted R2 = 0.20; β = 0.15; P = 0.043). This relationship between left ventricular mass and marinobufagenin excretion was evident in women (adjusted R2 = 0.06; β = 0.127; P = 0.015) but not in men (adjusted R2 = 0.06; β = 0.007; P = 0.92). Conclusions Left ventricular mass positively and independently associates with marinobufagenin excretion in young healthy adults with excessively high marinobufagenin excretion. Women may be more sensitive to the effects of marinobufagenin on early structural cardiac changes.

Entities:  

Keywords:  Apparently healthy; left ventricular mass index; marinobufagenin; young adults

Mesh:

Substances:

Year:  2018        PMID: 29993282      PMCID: PMC6209078          DOI: 10.1177/2047487318788140

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


  31 in total

1.  Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy.

Authors:  L E Teichholz; T Kreulen; M V Herman; R Gorlin
Journal:  Am J Cardiol       Date:  1976-01       Impact factor: 2.778

Review 2.  A catalogue of reporting guidelines for health research.

Authors:  I Simera; D Moher; J Hoey; K F Schulz; D G Altman
Journal:  Eur J Clin Invest       Date:  2010-01       Impact factor: 4.686

3.  Stroke volume and cardiac output in normotensive children and adults. Assessment of relations with body size and impact of overweight.

Authors:  G de Simone; R B Devereux; S R Daniels; G Mureddu; M J Roman; T R Kimball; R Greco; S Witt; F Contaldo
Journal:  Circulation       Date:  1997-04-01       Impact factor: 29.690

4.  Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements.

Authors:  D J Sahn; A DeMaria; J Kisslo; A Weyman
Journal:  Circulation       Date:  1978-12       Impact factor: 29.690

5.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study.

Authors:  D Levy; R J Garrison; D D Savage; W B Kannel; W P Castelli
Journal:  N Engl J Med       Date:  1990-05-31       Impact factor: 91.245

6.  Marinobufagenin is an upstream modulator of Gadd45a stress signaling in preeclampsia.

Authors:  Mohammad N Uddin; Darijana Horvat; Sharon Demorrow; Enoch Agunanne; Jules B Puschett
Journal:  Biochim Biophys Acta       Date:  2010-09-17

7.  Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy.

Authors:  David J Kennedy; Sandeep Vetteth; Sankaridrug M Periyasamy; Mohamed Kanj; Larisa Fedorova; Samer Khouri; M Bashar Kahaleh; Zijian Xie; Deepak Malhotra; Nikolai I Kolodkin; Edward G Lakatta; Olga V Fedorova; Alexei Y Bagrov; Joseph I Shapiro
Journal:  Hypertension       Date:  2006-01-30       Impact factor: 10.190

8.  Coordinated shifts in Na/K-ATPase isoforms and their endogenous ligands during cardiac hypertrophy and failure in NaCl-sensitive hypertension.

Authors:  Olga V Fedorova; Mark I Talan; Natalia I Agalakova; Edward G Lakatta; Alexei Y Bagrov
Journal:  J Hypertens       Date:  2004-02       Impact factor: 4.844

9.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

10.  Monoclonal antibody to an endogenous bufadienolide, marinobufagenin, reverses preeclampsia-induced Na/K-ATPase inhibition and lowers blood pressure in NaCl-sensitive hypertension.

Authors:  Olga V Fedorova; Andrey S Simbirtsev; Nikolai I Kolodkin; Alexander Y Kotov; Natalia I Agalakova; Vladimir A Kashkin; Natalia I Tapilskaya; Anton Bzhelyansky; Vitaly A Reznik; Elena V Frolova; Elena R Nikitina; Georgy V Budny; Dan L Longo; Edward G Lakatta; Alexei Y Bagrov
Journal:  J Hypertens       Date:  2008-12       Impact factor: 4.844

View more
  10 in total

1.  Acute salt loading and cardiotonic steroids in resistant hypertension.

Authors:  Igor V Emelyanov; Alexandra O Konradi; Edward G Lakatta; Olga V Fedorova; Alexei Y Bagrov
Journal:  Curr Top Membr       Date:  2019-02-18       Impact factor: 3.049

2.  Effect of Cardiotonic Steroid Marinobufagenin on Vascular Remodeling and Cognitive Impairment in Young Dahl-S Rats.

Authors:  Yulia N Grigorova; Ondrej Juhasz; Jeffrey M Long; Valentina I Zernetkina; Mikayla L Hall; Wen Wei; Christopher H Morrell; Natalia Petrashevskaya; Audrey Morrow; Katherine H LaNasa; Alexei Y Bagrov; Peter R Rapp; Edward G Lakatta; Olga V Fedorova
Journal:  Int J Mol Sci       Date:  2022-04-20       Impact factor: 6.208

Review 3.  The Na+K+-ATPase Inhibitor Marinobufagenin and Early Cardiovascular Risk in Humans: a Review of Recent Evidence.

Authors:  Michél Strauss; Wayne Smith; Olga V Fedorova; Aletta E Schutte
Journal:  Curr Hypertens Rep       Date:  2019-04-12       Impact factor: 5.369

4.  Autonomic activity and its relationship with the endogenous cardiotonic steroid marinobufagenin: the African-PREDICT study.

Authors:  Michél Strauss; Wayne Smith; Wen Wei; Olga V Fedorova; Aletta E Schutte
Journal:  Nutr Neurosci       Date:  2019-01-07       Impact factor: 4.994

5.  The Effects of Short-Term Changes in Sodium Intake on Plasma Marinobufagenin Levels in Patients with Primary Salt-Sensitive and Salt-Insensitive Hypertension.

Authors:  Katarzyna Łabno-Kirszniok; Agata Kujawa-Szewieczek; Andrzej Wiecek; Grzegorz Piecha
Journal:  Nutrients       Date:  2021-04-29       Impact factor: 5.717

6.  Microvascular function in non-dippers: Potential involvement of the salt sensitivity biomarker, marinobufagenin-The African-PREDICT study.

Authors:  Michél Strauss-Kruger; Wayne Smith; Wen Wei; Alexei Y Bagrov; Olga V Fedorova; Aletta E Schutte
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-12-24       Impact factor: 2.885

7.  Monoclonal Antibody to Marinobufagenin Downregulates TGFβ Profibrotic Signaling in Left Ventricle and Kidney and Reduces Tissue Remodeling in Salt-Sensitive Hypertension.

Authors:  Yongqing Zhang; Wen Wei; Victoria Shilova; Natalia N Petrashevskaya; Valentina I Zernetkina; Yulia N Grigorova; Courtney A Marshall; Rachel C Fenner; Elin Lehrmann; William H Wood; Kevin G Becker; Edward G Lakatta; Alexei Y Bagrov; Olga V Fedorova
Journal:  J Am Heart Assoc       Date:  2019-10-02       Impact factor: 6.106

8.  The African Prospective study on the Early Detection and Identification of Cardiovascular disease and Hypertension (African-PREDICT): Design, recruitment and initial examination.

Authors:  Aletta E Schutte; Philimon N Gona; Christian Delles; Aletta S Uys; Adele Burger; Catharina Mc Mels; Ruan Kruger; Wayne Smith; Carla Mt Fourie; Shani Botha; Leandi Lammertyn; Johannes M van Rooyen; Lebo F Gafane-Matemane; Gontse G Mokwatsi; Yolandi Breet; H Salome Kruger; Tertia van Zyl; Marlien Pieters; Lizelle Zandberg; Roan Louw; Sarah J Moss; Itumeleng P Khumalo; Hugo W Huisman
Journal:  Eur J Prev Cardiol       Date:  2019-01-06       Impact factor: 7.804

Review 9.  Cardiotonic Steroids-A Possible Link Between High-Salt Diet and Organ Damage.

Authors:  Aneta Paczula; Andrzej Wiecek; Grzegorz Piecha
Journal:  Int J Mol Sci       Date:  2019-01-30       Impact factor: 5.923

10.  The Cardiotonic Steroid Marinobufagenin Is a Predictor of Increased Left Ventricular Mass in Obesity: The African-PREDICT Study.

Authors:  Michél Strauss-Kruger; Ruan Kruger; Wayne Smith; Lebo F Gafane-Matemane; Gontse Mokwatsi; Wen Wei; Olga V Fedorova; Aletta E Schutte
Journal:  Nutrients       Date:  2020-10-18       Impact factor: 5.717

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.